公开(公告)号：KR1020040051282A

公开(公告)日：2004-06-18

申请号：KR1020020079182

申请日：2002-12-12

Applicant: 한국전자통신연구원

Inventor： 정명애 ,  전길자 ,  이윤실

IPC: B82B3/00 ,  B82Y5/00 ,  B82Y40/00 ,  A61K9/51

CPC classification number: A61K9/51 ,  A61K31/047 ,  A61K31/16 ,  B82Y5/00 ,  B82Y40/00

Abstract: PURPOSE: Smart nanoparticles containing oleamide or monoacetyl diglyceride(MADG), medicinal components, in the core of the micelle composed of poly(N-vinyl caprolactam) are provided to show good selectivity for diseased organs, and decrease ill effects on the normal cells and the dosage needed. CONSTITUTION: The smart nanoparticles(50), being 50-300nm in size, are prepared by the following steps of: (i) mixing medicinal materials, N-vinyl caprolactam monomer and surfactant for emulsifying, wherein the medical materials are oleamide extracted from ganoderma lucidum karst and monoacetyl diglyceride extracted from deer antlers, and the surfactant is an anion surfactant such as sodium dodecyl sulfate(SDS) or cationic surfactant such as cetyltrimethyl ammonium bromide(CTAB) and the amount of surfactant is between the first critical micelle concentration(CMC) and the second critical micelle concentration; (ii) polymerizing the emulsified caprolactam monomer at 40-90deg.C with stirring in a rate of 500-2000rpm to control the size of nanoparticles, wherein 0.1-1wt.% of polymerizing initiator(based on the total amount of N-vinyl caprolactam monomer) such as potassium persulfate or ammonium persulfate is used. The medicinal material such as MADG or oleamide is encapsulated in a core(52) of nanoparticles and the core is encapsulated in a micelle(54) comprising N-vinyl caprolactam monomer.

Abstract translation: 目的：提供含有油酰胺或单乙酰己二酸甘油酯（MADG）的智能纳米颗粒，其是由聚（N-乙烯基己内酰胺）构成的胶束芯中的药物组分，以显示对患病器官的良好选择性，并减少对正常细胞的不良影响， 所需剂量。 构成：尺寸为50-300nm的智能纳米颗粒（50）通过以下步骤制备：（i）将医药材料，N-乙烯基己内酰胺单体和用于乳化的表面活性剂混合，其中医用材料是从灵芝中提取的油酰胺 灵芝岩溶和从鹿角鹿提取的单乙酰甘油二酯，表面活性剂是十二烷基硫酸钠（SDS）或阳离子表面活性剂如十六烷基三甲基溴化铵（CTAB）等阴离子表面活性剂，表面活性剂的量介于第一临界胶束浓度 ）和第二临界胶束浓度; （ii）在搅拌下以500-2000rpm的速度在40-90℃下聚合乳化的己内酰胺单体以控制纳米颗粒的尺寸，其中0.1-1重量％的聚合引发剂（基于N-乙烯基己内酰胺的总量 单体）如过硫酸钾或过硫酸铵。 将药物材料如MADG或油酰胺包封在纳米颗粒的核心（52）中，并将核心包封在包含N-乙烯基己内酰胺单体的胶束（54）中。

公开(公告)号：KR1020030070662A

公开(公告)日：2003-09-02

申请号：KR1020020010139

申请日：2002-02-26

Applicant: 한국전자통신연구원

Inventor： 정명애 ,  정상돈

IPC: A61K9/127 ,  B82B3/00 ,  B82Y40/00

CPC classification number: A61K9/1075 ,  A61K31/337 ,  A61K33/24 ,  A61K41/0071 ,  B82Y5/00 ,  B82Y40/00

Abstract: PURPOSE: A process of preparing smart nano-particles in which a therapeutic drug is uniformly dispersed within nano-particles by introducing the therapeutic drug into the reaction system during emulsion polymerization of the nano-particles and then polymerizing it is provided. The nano-particles selectively concentrate on a target organ such as cancer cells, etc. by enhanced permeation and retention effect, thereby exhibiting treatment improving effect. CONSTITUTION: A therapeutic drug and a monomer are agitated at 50 to 90deg.C with a surfactant to emulsify, the emulsified monomer is polymerized in an emulsion particle to produce nano-particles. The therapeutic drug is one or more photo-treating drugs selected from porphyrin, phthalocyanine and a derivative thereof. The monomer is one or more selected from anhydride, glycolide, lactide, caprolactone and N-vinylcaprolactame. The surfactant is one or more selected from cetyl trimethyl ammonium bromide as a cationic surfactant and sodium dodecyl sulfate as an anionic surfactant.

Abstract translation: 目的：提供一种通过在纳米粒子的乳液聚合过程中将治疗药物引入反应体系中，然后使其聚合而制备治疗药物在纳米颗粒内均匀分散的智能纳米颗粒的方法。 通过提高渗透和保留效果，纳米粒子选择性地浓缩在靶器官如癌细胞等上，从而表现出治疗改善效果。 构成：将治疗药物和单体用50〜90℃的表面活性剂搅拌，乳化的单体在乳液颗粒中聚合，生成纳米粒子。 治疗药物是选自卟啉，酞菁及其衍生物的一种或多种光处理药物。 单体是选自酸酐，乙交酯，丙交酯，己内酯和N-乙烯基己内酰胺的一种或多种。 表面活性剂是选自十六烷基三甲基溴化铵作为阳离子表面活性剂和十二烷基硫酸钠作为阴离子表面活性剂的一种或多种。